Pulmonary alveolar microlithiasis: a case report and review of the literature

Proesmans, M.; Boon, Mieke; Verbeken, Eric; Özçeli̇k, Uğur; Ki̇per, Nural; Casseye, W Van de; Boeck, K. De

doi:10.1007/s00431-012-1678-8

Cited by 20 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of diphosphonates has also been proposed to reduce calcium phosphate precipitation in PAM. However, this therapy remains controversial given the limited number of reports in the literature [38,39,[60][61][62]. In 1988, the Toronto Lung Transplantation Group reported a successful double lung transplantation in humans.…”

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide

et al. 2015

View full text Add to dashboard Cite

Pulmonary alveolar microlithiasis (PAM) is a rare disease characterised by the widespread intra-alveolar accumulation of minute calculi called microliths. It is caused by mutation of the SLC34A2 gene encoding the type IIb sodium phosphate cotransporter in alveolar type II cells. The present study explores the epidemiological, familial, genetic, clinical, diagnostic, radiological and therapeutic aspects with the aim of contributing to a better understanding of this uncommon disease.We searched articles on PAM published up to December 2014 and 544 papers were found, accounting for 1022 cases.PAM is present in all continents and in many nations, in particular in Turkey, China, Japan, India, Italy and the USA. Familiality is frequent. The clinical course is not uniform and the causes of this clinical variability seem to be largely nongenetic. The optimal diagnostic procedure is the association of chest high-resolution computed tomography (HRCT) with bronchoalveolar lavage, but a chest radiograph may suffice in families in which a case has already been diagnosed. Moreover, chest radiography and HRCT allow the classification of the evolutionary phase of the disease and its severity. At present lung transplantation is the only effective therapy. However, better knowledge of the gene responsible offers hope for new therapies. @ERSpublications Familial, genetic, clinical, radiological and therapeutic aspects of pulmonary alveolar microlithiasis epidemiology http://ow.ly/St3Mw

show abstract

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Pulmonary alveolar microlithiasis a rare genetic disease characterized by abnormal calcium deposition throughout some organs, especially the lungs . The diagnosis is often incidental, as in the present cases.…”

Section: Discussionmentioning

confidence: 67%

Diagnosis and treatment of pulmonary alveolar microlithiasis

Emiralioğlu

Beken

Özcan

et al. 2016

Pediatrics International

View full text Add to dashboard Cite

Pulmonary alveolar microlithiasis (PAM) is a rare genetic disease caused by mutations in sodium-phosphate co-transporter (SLC34A2), which encodes a type 2b sodium phosphate co-transporter. Disease is characterized by intra-alveolar microlith formation of phosphate. Turkey has a high prevalence of PAM. Herein, we report the clinical and radiological findings of three patients diagnosed with PAM and treated with disodium etidronate.

show abstract

“…Systemic corticosteroids, calcium-chelating agents (alendronate sodium can have palliative role) and serial bronchopulmonary lavage have been shown to be ineffective and are used as palliative treatments [8,9,10]. The use of diphosphonates has also been proposed to reduce calcium phosphate precipitation in PAM, however, this therapy remains controversial given the limited number of reports in the literature [11][12][13][14][15].…”

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

Pulmonary Alveolar Microlithiasis and Rheumatoid Arthritis with Pulmonary Tuberculosis

Sharma¹,

Uppe²,

Patel³

et al. 2018

AJIM

View full text Add to dashboard Cite

Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive disease, characterised by widespread intra-alveolar accumulation of microliths. A 30-year-old male patient, known case of rheumatioid arthritis on treatment, presented with occasional complaints of cough with expectoration, since 1 year. He was found to be sputum AFB positive for which AKT was started, and a chest xray was advised, which showed diffuse bilateral micronodular calcific opacities having sand-like appearance distributed throughout the lungs, with a evident black pleural sign, which made us suspect PAM. An HRCT chest showed, multiple dense micronodular opacities in bilateral lung parenchyma prominently in the middle and lower lung zones giving a classical sandstorm appearance with sparing of a thin peripheral subpleural rim of parenchyma, giving a black pleura sign. The patient was symptomatically treated and was counselled for lung transplant and presents for regular follow up.

show abstract

Pulmonary alveolar microlithiasis: a case report and review of the literature

Cited by 20 publications

References 18 publications

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide

Diagnosis and treatment of pulmonary alveolar microlithiasis

Pulmonary Alveolar Microlithiasis and Rheumatoid Arthritis with Pulmonary Tuberculosis

Contact Info

Product

Resources

About